European Commission extends Zytiga(Janssen Cilag) indication in Prostate Cancer
Janssen-Cilag has announced that the European Commission has approved an extension to the licence of Zytiga (abiraterone acetate), to include its use in combination with prednisone or prednisolone, for the treatment of metastatic castration-resistant Prostate Cancer (mCRPC) in men who have failed on androgen deprivation therapy in whom chemotherapy is not yet indicated. The oral, once-daily drug, with prednisone and prednisolone, has only been approved to treat men with mCRPC whose disease has progressed on or after a docetaxel-based chemotherapy. The FDA granted a similar extension in the US last month.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins